← Leaderboards
Andrea Cercek
Sloan-Kettering Inst Can Research
$4,410,417
Attributed
$9,457,861
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2020–25$2.5M$1.9M$1.3M$625K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,457,861 · 4
By mechanism
U01$8,201,686 · 2
R01$805,200 · 1
R21$450,975 · 1
Top collaborators
- Jessica Scott6 shared
- Christine A Iacobuzio-Donahue5 shared
- William Robert Jarnagin5 shared
- Rona Yaeger2 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Jesse Joshua Smith$3,709,431
- William Robert Jarnagin$4,049,789
- Amber Simpson$1,284,179
- Yun Shin Chun$1,158,484
- Richard Kinh Gian Do$1,284,179
Others in their field
Other Emerging Leaders on “Response”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$195,683,539
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
Research focus
ResponseOperative Surgical ProceduresChemotherapyIncidenceTumorDiagnosisRegimenPharmaceutical PreparationsToxic EffectMalignant NeoplasmsEvaluationOncologyPatient PopulationPrimary EndpointDoseReportingNeoadjuvant TherapyEnrollmentSiteDesignLocal TherapyPathologicClinical TrialsRectal Cancer
Grant awards (15)
Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer$1,224,361
U01 · FY2025 · CA
Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer$402,600
R01 · FY2025 · CA · contact PI
Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer$1,101,776
U01 · FY2024 · CA
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)$623,923
U01 · FY2024 · CA
Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer$402,600
R01 · FY2024 · CA · contact PI
Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer$11,312
U01 · FY2024 · CA
Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer$1,246,572
U01 · FY2023 · CA
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)$642,310
U01 · FY2023 · CA
Diversity Supplement: Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer$69,382
U01 · FY2023 · CA
Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer$1,284,278
U01 · FY2022 · CA
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)$649,386
U01 · FY2022 · CA
Neoadjuvant PD-1 blockade in mismatch repair deficient rectal cancer$202,732
R21 · FY2022 · CA · contact PI
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)$665,665
U01 · FY2021 · CA
Neoadjuvant PD-1 blockade in mismatch repair deficient rectal cancer$248,243
R21 · FY2021 · CA · contact PI
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)$682,721
U01 · FY2020 · CA